Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
| Market Cap | 3.17B+5.5% |
| Revenue (ttm) | 606.33M+105.2% |
| Net Income | -46.48M+49.5% |
| EPS | -1.09+53.2% |
| Shares Out | 43.02M |
| PE Ratio | n/a |
| Forward PE | 51.84 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 405,145 |
| Open | 73.58 |
| Previous Close | 74.11 |
| Day's Range | 73.30 - 74.67 |
| 52-Week Range | 53.89 - 91.53 |
| Beta | 0.54 |
| Analysts | Buy |
| Price Target | 103.00(+39.93%) |
| Earnings Date | Nov 3, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About TARS
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$TARS stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in TARS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TARS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TARS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
TARS Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Product sales, net | $173.91M | 65.90% |
| Selling and marketing | $90.00M | 34.10% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New TARS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TARS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in TARS
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $96.47M |
| IWMiShares Russell 2000 ETF | $81.01M |
| VXFVanguard Extended Market ETF | $34.19M |
| IWOiShares Russell 2000 Growth ETF | $29.05M |
| IBBiShares Biotechnology ETF | $23.13M |
| PJPInvesco Pharmaceuticals ETF | $18.42M |
Estimated from each fund’s disclosed top holdings × AUM
TARS Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from TARS’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score